⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AZN News
AstraZeneca PLC
Leading Chinese Innovative Medical Device Maker Insight Lifetech Has Successfully Listed on STAR Market USA - English APAC - Traditional Chinese USA - English
prnewswire.com
AAPL
TSLA
XOM
MSFT
GOOGL
AMZN
NVDA
META
BRK.A
JPM
V
JNJ
PG
MA
HD
UNH
DIS
BAC
PFE
MRK
TMO
ABT
MDT
BMY
AMGN
GILD
AZN
LLY
BIIB
REGN
VRTX
ALGN
ISRG
TDOC
EXAS
ZLAB
SCHR
APT
BILI
HSAI
UBOT
TIGR
INSM
YXT
CCEL
IMUX
INCY
CRSP
EDIT
NTLA
SRPT
EXEL
LULU
CROX
NKE
CPRI
PVH
RL
URBN
M
KSS
TJX
BBY
ROST
DLTR
WMT
TGT
COST
SBUX
MCD
CMG
YUM
QSR
CBRL
TXRH
NDSN
TTWO
EA
NTDOY
SONY
MSGS
AMC
IMAX
RCL
CCL
NCLH
AAL
DAL
UAL
LUV
ALK
JBLU
SKX
ADBE
CRM
INTC
AMD
QCOM
AMAT
MU
NXPI
SNPS
CDNS
ASML
PAYX
ADP
NOW
CSCO
ORCL
IBM
HPQ
DELL
ACN
INFY
SAP
ERIC
NOK
STM
UL
PEP
KO
Dubai Science Park celebrates two decades of enabling science to strengthen knowledge- and innovation-led economy USA - English Middle East - Arabic Middle East - English
prnewswire.com
AMZN
PFE
AZN
BSX
TMO
ISPE Announces 2026 Facility of the Year Awards (FOYA) Submission Finalists at the 2026 ISPE Facilities of the Future Conference
prnewswire.com
AZN
DNLI
LLY
JNJ
MRK
MRNA
Levicept Announces the Appointment of James Sandy as Chief Development Officer
globenewswire.com
PFE
AZN
Clinical Trials Support Service Market to Reach US$ 47.1 Billion by 2032 Driven by Rising Trial Complexity, Patient-Centric Models, and AI-Based Trial Management | Astute Analytica
globenewswire.com
PFE
MRK
JNJ
BMY
GILD
AMGN
REGN
LLY
ABBV
AZN
Independent Multi-Vendor Study Validates BostonGene’s AI for Precision HER2 Scoring
businesswire.com
AZN
BMY
AMGN
MRK
GSK
Cancer Immunotherapy Research Report 2026: Market Forecasts 2025-2029 for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer with Executive and Consultant Guides
globenewswire.com
ABBV
ADAG
ADAP
ACET
ALXO
AMBR
AMGN
RCUS
AZN
ATRC
BBLU
BIIB
BNTX
BOLT
BMY
CRBU
CLDX
CRVS
LLY
EVAX
GNSS
GILD
GLSI
IMUX
IMMX
IMNM
INCY
INDP
ISRL
IOBT
JNJ
MRK
MRNA
MBIO
NVS
NVX
PDSB
PFE
REGN
SNY
SNT
URGN
ZYME
DATROWAY ® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy
businesswire.com
AZN
DATROWAY ® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
businesswire.com
AZN
TIGIT Inhibitors Market Poised for Strong Growth Through 2034, Driven by Expanding Immuno-Oncology Pipeline | DelveInsight
prnewswire.com
RCUS
GILD
AZN
CGEN
CHRS